Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBZMYT)

• Drug Name: Pyridine derivative 18 Drug Info
• Synonyms: PMID27646564-Compound-5
• Cross-matching ID: TTD Drug ID: DMBZMYT

Molecule-Related Drug Atlas

Drug(s) Targeting Macrophage colony-stimulating factor 1 receptor (CSF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[2]
Sulfatinib	DMPOTM4	Neuroendocrine cancer	2B72.1	Phase 3	[3]
ARRY-382	DM0VGDC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[3]
BLZ-945	DMG1LVA	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[3]
Cabiralizumab	DMGE058	Pancreatic cancer	2C10	Phase 2	[4]
FPA-008	DM3ZN6Y	Autoimmune diabetes	5A10	Phase 1/2	[5]
DCC-3014	DMHW289	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
PLX7486	DM0IVGU	Pancreatic cancer	2C10	Phase 1	[3]
TPX-0022	DMC2IJN	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
SNDX-6352	DM8ZROW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

Drug(s) Targeting Platelet-derived growth factor receptor alpha (PDGFRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[8]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[9]
Olaratumab	DMNYOIX	Soft tissue sarcoma	2B57	Approved	[10]
Avapritinib	DMK2GZX	Gastrointestinal stromal tumour	2B5B	Approved	[11]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[12]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[13]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]
MP470	DMELUAK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[16]
MEDI-575	DMI9WVM	Glioblastoma multiforme	2A00.0	Phase 2	[17]

Drug(s) Targeting Tyrosine-protein kinase Kit (KIT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[18]
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[19]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[20]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[21]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[21]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[22]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[2]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[9]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]

Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[19]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[8]
Becaplermin	DM1R5X4	Diabetic complication	5A2Y	Approved	[23]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[12]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[15]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[24]
SNN-0031	DM2X3BR	Brain injury	NA07.Z	Phase 1/2	[25]
TAK-593	DMNFZOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]
PMID25656651-Compound-21a	DMCKAON	N. A.	N. A.	Patented	[27]

Drug(s) Targeting Proto-oncogene c-Ret (RET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[28]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[21]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[21]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[18]
Selpercatinib	DMZR15V	Non-small-cell lung cancer	2C25.Y	Approved	[29]
Pralsetinib	DMWU0I2	Non-small-cell lung cancer	2C25.Y	Approved	[30]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[31]
CEP-32496	DMAO04B	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[32]
GSK3179106	DM2KCIP	Inflammatory bowel disease	DD72	Phase 1	[33]

Drug(s) Targeting Fms-like tyrosine kinase 3 (FLT-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[34]
Ponatinib	DMYGJQO	Acute lymphoblastic leukaemia	2A85	Approved	[21]
Intedanib	DMSTA36	Colorectal cancer	2B91.Z	Approved	[35]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[18]
Gilteritinib	DMWQ4MZ	Acute myeloid leukaemia	2A60	Approved	[36]
Pexidartinib	DMS2J0Z	Tenosynovial giant cell tumour	2F7B	Approved	[2]
Lestaurtinib	DMQ2AIJ	Acute myeloid leukaemia	2A60	Approved (orphan drug)	[37]
Pacritinib	DM1T6ZN	Myelofibrosis	2A20.2	Phase 3	[34]
AC220	DM8Y4JS	Acute myeloid leukaemia	2A60	Phase 3	[3]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[14]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[19]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[38]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[21]
Sunitinib	DMCBJSR	Gastrointestinal cancer	2C11	Approved	[39]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[40]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[18]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[22]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[41]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[42]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[43]

Drug(s) Targeting Proto-oncogene c-Src (SRC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[18]
Bosutinib	DMTI8YE	Breast cancer	2C60-2C65	Approved	[18]
SKI-758	DMQ8E9R	Ischemia	8B10-8B11	Approved	[44]
Herbimycin A	DM6YWBF	Solid tumour/cancer	2A00-2F9Z	Approved	[45]
Al3818	DM3WP0N	Alveolar soft part sarcoma	2A60-2C35	Phase 3	[3]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[3]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[33]
KX-01	DMF0NA9	Actinic keratosis	EK90.0	Phase 3	[46]
Saracatinib	DMBLHGP	Hematologic tumour	2B33.Y	Phase 2	[47]
TPX-0046	DMIVE67	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[32]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fms-like tyrosine kinase 3 (FLT-3)	TTGJCWZ	FLT3_HUMAN	Inhibitor	[1]
Macrophage colony-stimulating factor 1 receptor (CSF1R)	TT7MRDV	CSF1R_HUMAN	Inhibitor	[1]
Platelet-derived growth factor receptor alpha (PDGFRA)	TT8FYO9	PGFRA_HUMAN	Inhibitor	[1]
Platelet-derived growth factor receptor beta (PDGFRB)	TTI7421	PGFRB_HUMAN	Inhibitor	[1]
Proto-oncogene c-Ret (RET)	TT4DXQT	RET_HUMAN	Inhibitor	[1]
Proto-oncogene c-Src (SRC)	TT6PKBN	SRC_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase Kit (KIT)	TTX41N9	KIT_HUMAN	Inhibitor	[1]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[1]

References

• [1] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals.
• [7] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [8] Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [10] A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [12] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [13] The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
• [14] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [15] National Cancer Institute Drug Dictionary (drug id 452042).
• [16] Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
• [17] Clinical pipeline report, company report or official report of MedImmune (2011).
• [18] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [19] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [20] New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23.
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [22] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [24] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [25] Company report (Neuronova)
• [26] Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
• [27] Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
• [28] Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96.
• [29] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [30] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [31] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185).
• [32] Clinical pipeline report, company report or official report of Turning Point Therapeutics.
• [33] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [34] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807).
• [35] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [36] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [37] Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71.
• [38] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [39] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [40] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [41] Clinical pipeline report, company report or official report of Exelixis (2011).
• [42] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [43] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [44] Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
• [45] In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
• [46] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [47] Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.